Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Blood (2024) 144 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2024-202392

Published: 2024

Journal Articles

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2024-202937

Published: 2024

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2023-173317

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi

Blood (2022) 140 (Supplement 1): 10131–10132.

https://doi.org/10.1182/blood-2022-164722

Published: 2022

Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Blood (2022) 140 (Supplement 1): 4426–4427.

https://doi.org/10.1182/blood-2022-164572

Published: 2022

Journal Articles

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Shimrit Harlev, Nashwa Fadaos, Tehila Azoulay, Ronit Leiba, Nurit Horesh, Tsofia Inbar, Netanel A. Horowitz, Inna Tsoran-Rosenthal, Noa Lavi, Eldad J. Dann, Tsila Zuckerman

Blood (2022) 140 (Supplement 1): 6534–6535.

https://doi.org/10.1182/blood-2022-166233

Published: 2022

Journal Articles

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Yael C Cohen, Mor Zada, Shuang-Yin Wang, Ohad S. Bentur, Evgeni Chubar, Amos Cohen, Noa Lavi, Hila Magen, Moshe Gatt, Miri Zektser, Merav Leiba, Galia Stemer, Tamir Shragai, Irit Avivi, Assaf Weiner, Ido Amit

Blood (2021) 138 (Supplement 1): 2725.

https://doi.org/10.1182/blood-2021-149701

Published: 2021

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139670

Published: 2020

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Blood (2018) 132 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2018-99-114106

Published: 2018

Journal Articles

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Noam Benyamini, MD, Adir S, MD, Moshe E. Gatt, MD, Yael C Cohen, MD, Irit Avivi, MD, Svetlana Trestman, MD, Olga Shvetz, MD, Tamar Tadmor, MD, Najib Dally, MD, Yevgeny Chober, Hila Magen, MD, Chezi Ganzel, MD, Osnat Jarchowcky Dolberg, Celia Suriu, MD, Noa Lavi, MD

Blood (2018) 132 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2018-99-115985

Published: 2018

Journal Articles

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Tamir Shragai, MD, Moshe E. Gatt, MD, Adir Shaulov, MD, Eirini Katodritou, MD, Theodora Triantafyllou, MD, Noa Lavi, MD, Anastasia Pouli, MD PhD, Anastasia Sioni, Iuliana Vaxman, MD BA, Miri Zektser, MD, Chezi Ganzel, MD, Noam Benyamini, MD, Svetlana Trestman, MD, Tomer ziv Baran, PhD, Yael C Cohen, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 5578.

https://doi.org/10.1182/blood-2018-99-116372

Published: 2018

Journal Articles

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Yael C Cohen, Hila Magen, MD, Noa Lavi, MD, Moshe E. Gatt, MD, Evgeni Chubar, MD, Natalia Kreiniz, Tamar Tadmor, MD, Svetlana Trestman, MD, Roy Vitkon, MD, Ory Rouvio, Olga Shvetz, MD, Adir Shaulov, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2018-99-114217

Published: 2018

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Merav Barzilai, MD, Ilya Kirgner, MD, Martin Ellis, MD, Irit Avivi, MD, Najib Dally, MD, Uri Rozovski, Noa Lavi, MD

Blood (2017) 130 (Supplement 1): 2917.

https://doi.org/10.1182/blood.V130.Suppl_1.2917.2917

Published: 2017

Journal Articles

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Sharon Ben Barouch, MD, Yair Herishanu, MD, Nadav Sarid, MD, Chava Perry, Irit Avivi, MD, Lev Shvidel, MD, Osnat Bairey, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Abraham Avigdor, MD, Neta Goldschmidt, MD, Eyal Lebel, MD, Orit Sofer

Blood (2017) 130 (Supplement 1): 1563.

https://doi.org/10.1182/blood.V130.Suppl_1.1563.1563

Published: 2017

Journal Articles

Beac and BEAM High-Dose Chemotherapy in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation Are Efficacious, with Comparable Toxicity

Noa Lavi, MD, Ron Ram, MD, Odelia Amit, MD, Netanel A Horowitz, MD, Tzila Zuckerman, MD

Blood (2016) 128 (22): 5828.

https://doi.org/10.1182/blood.V128.22.5828.5828

Published: 2016

NARROW

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Characteristics, Management and Outcome of DLBCL Patients Presenting with Simultaneous Systemic and CNS Disease at Diagnosis - a Retrospective Multicenter Study

Beac and BEAM High-Dose Chemotherapy in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation Are Efficacious, with Comparable Toxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only